Moderna files for authorization of its covid-19 vaccine in young children six months to under six years of age

Submission to regulators globally is based on phase 2/3 studies of mrna-1273 in young children cambridge, ma / accesswire / april 28, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has submitted a request for emergency use authorization (eua) for its covid-19 vaccine (mrna-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the u.s. food and drug administration and that similar requests are underway with international regulatory authorities. the requests are based on a 25 Μg two-dose primary series of mrna-1273.
MRNA Ratings Summary
MRNA Quant Ranking